OAM
NBIX icon

Oberweis Asset Management’s Neurocrine Biosciences NBIX Stock Holding History

Oberweis Asset Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-4,700
Closed -$214K – 159
2016
Q2 		$214K Buy
+4,700
New +$216K 0.06% 161

Other funds holding NBIX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Oberweis Asset Management's NBIX Position: Q3 2016 in Review

Oberweis Asset Management sold out of Neurocrine Biosciences (NBIX) in Q3 2016, closing a stake of 4,700 shares — an estimated $214K sold.

Oberweis Asset Management first reported a position in NBIX in Q2 2016 and held it in 1 quarter. The position peaked at $214K in Q2 2016. 244 funds tracked by Wall St. Rank hold NBIX as of Q3 2016.

  • Oberweis Asset Management reported no remaining Neurocrine Biosciences position as of Q3 2016 after selling out during the quarter.
  • Oberweis Asset Management sold 4,700 Neurocrine Biosciences shares in Q3 2016, an estimated $214K.
  • Oberweis Asset Management first reported a position in Neurocrine Biosciences in Q2 2016 and held it in 1 quarter.
  • Oberweis Asset Management's Neurocrine Biosciences position peaked at $214K in Q2 2016.
  • 244 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2016.

Based on Oberweis Asset Management's 13F filing for Q3 2016, filed 14 Nov 2016.